{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T15:45:36Z","timestamp":1777045536391,"version":"3.51.4"},"reference-count":92,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s40263-025-01247-8","type":"journal-article","created":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T08:49:13Z","timestamp":1762937353000},"page":"59-70","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Potential Clinical Use of Opioid-Receptor-Modulating Drugs in Bipolar Disorder"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-8938-5985","authenticated-orcid":false,"given":"Maria","family":"Gefke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1840-7936","authenticated-orcid":false,"given":"Christina B.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger S.","family":"McIntyre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5982-1335","authenticated-orcid":false,"given":"Maj","family":"Vinberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,12]]},"reference":[{"issue":"10265","key":"1247_CR1","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1016\/S0140-6736(20)31544-0","volume":"396","author":"RS McIntyre","year":"2020","unstructured":"McIntyre RS, et al. Bipolar disorders. Lancet. 2020;396(10265):1841\u201356.","journal-title":"Lancet"},{"issue":"2\u20133","key":"1247_CR2","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jad.2013.02.001","volume":"148","author":"A Fagiolini","year":"2013","unstructured":"Fagiolini A, et al. Prevalence, chronicity, burden and borders of bipolar disorder. J Affect Disord. 2013;148(2\u20133):161\u20139.","journal-title":"J Affect Disord"},{"issue":"7","key":"1247_CR3","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/j.comppsych.2014.05.009","volume":"55","author":"M Martin-Subero","year":"2014","unstructured":"Martin-Subero M, et al. Quality of life in bipolar and schizoaffective disorder\u2014a naturalistic approach. Compr Psychiatry. 2014;55(7):1540\u20135.","journal-title":"Compr Psychiatry"},{"key":"1247_CR4","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.jad.2021.07.065","volume":"294","author":"LV Kessing","year":"2021","unstructured":"Kessing LV, et al. A nation-wide population-based longitudinal study on life expectancy and cause specific mortality in patients with bipolar disorder and their siblings. J Affect Disord. 2021;294:472\u20136.","journal-title":"J Affect Disord"},{"issue":"14","key":"1247_CR5","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1001\/jama.2023.18588","volume":"330","author":"AA Nierenberg","year":"2023","unstructured":"Nierenberg AA, et al. Diagnosis and treatment of bipolar disorder: a review. JAMA. 2023;330(14):1370\u201380.","journal-title":"JAMA"},{"issue":"7","key":"1247_CR6","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1586\/ern.09.62","volume":"9","author":"M Pompili","year":"2009","unstructured":"Pompili M, et al. Improving adherence in mood disorders: the struggle against relapse, recurrence and suicide risk. Expert Rev Neurother. 2009;9(7):985\u20131004.","journal-title":"Expert Rev Neurother"},{"key":"1247_CR7","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.jad.2020.07.109","volume":"276","author":"M Fornaro","year":"2020","unstructured":"Fornaro M, et al. The concept and management of acute episodes of treatment-resistant bipolar disorder: a systematic review and exploratory meta-analysis of randomized controlled trials. J Affect Disord. 2020;276:970\u201383.","journal-title":"J Affect Disord"},{"issue":"2","key":"1247_CR8","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1590\/1516-4446-2020-1627","volume":"44","author":"AP Diaz","year":"2022","unstructured":"Diaz AP, et al. Treatment-resistant bipolar depression: concepts and challenges for novel interventions. Braz J Psychiatry. 2022;44(2):178\u201386.","journal-title":"Braz J Psychiatry"},{"issue":"6","key":"1247_CR9","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1017\/S1092852924002189","volume":"29","author":"RS McIntyre","year":"2024","unstructured":"McIntyre RS, et al. Opioid antagonists: clinical utility, pharmacology, safety, and tolerability. CNS Spectr. 2024;29(6):542\u20138.","journal-title":"CNS Spectr"},{"key":"1247_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19082410","author":"G Serafini","year":"2018","unstructured":"Serafini G, et al. The efficacy of buprenorphine in major depression, treatment-resistant depression and suicidal behavior: a systematic review. Int J Mol Sci. 2018. https:\/\/doi.org\/10.3390\/ijms19082410.","journal-title":"Int J Mol Sci"},{"key":"1247_CR11","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.pharmthera.2019.04.009","volume":"201","author":"CA Browne","year":"2019","unstructured":"Browne CA, Lucki I. Targeting opioid dysregulation in depression for the development of novel therapeutics. Pharmacol Ther. 2019;201:51\u201376.","journal-title":"Pharmacol Ther"},{"key":"1247_CR12","doi-asserted-by":"crossref","DOI":"10.1016\/j.neubiorev.2022.104800","volume":"140","author":"LA Jelen","year":"2022","unstructured":"Jelen LA, et al. The opioid system in depression. Neurosci Biobehav Rev. 2022;140:104800.","journal-title":"Neurosci Biobehav Rev"},{"issue":"4","key":"1247_CR13","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/s41380-018-0117-2","volume":"24","author":"M Pecina","year":"2019","unstructured":"Pecina M, et al. Endogenous opioid system dysregulation in depression: implications for new therapeutic approaches. Mol Psychiatry. 2019;24(4):576\u201387.","journal-title":"Mol Psychiatry"},{"key":"1247_CR14","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2020.170348","volume":"132","author":"RJ Bodnar","year":"2020","unstructured":"Bodnar RJ. Endogenous opiates and behavior: 2018. Peptides. 2020;132:170348.","journal-title":"Peptides"},{"issue":"3","key":"1247_CR15","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1017\/S1092852922000116","volume":"28","author":"RS McIntyre","year":"2023","unstructured":"McIntyre RS, et al. Opioid antagonism mitigates antipsychotic-associated weight gain: focus on olanzapine. CNS Spectr. 2023;28(3):288\u201399.","journal-title":"CNS Spectr"},{"issue":"14","key":"1247_CR16","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1111\/bph.13812","volume":"175","author":"L Nummenmaa","year":"2018","unstructured":"Nummenmaa L, Tuominen L. Opioid system and human emotions. Br J Pharmacol. 2018;175(14):2737\u201349.","journal-title":"Br J Pharmacol"},{"issue":"3","key":"1247_CR17","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/00004850-198807000-00007","volume":"3","author":"MM Weber","year":"1988","unstructured":"Weber MM, Emrich HM. Current and historical concepts of opiate treatment in psychiatric disorders. Int Clin Psychopharmacol. 1988;3(3):255\u201366.","journal-title":"Int Clin Psychopharmacol"},{"issue":"Suppl 6","key":"1247_CR18","first-page":"4","volume":"61","author":"RM Hirschfeld","year":"2000","unstructured":"Hirschfeld RM. History and evolution of the monoamine hypothesis of depression. J Clin Psychiatry. 2000;61(Suppl 6):4\u20136.","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"1247_CR19","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/10550880802122646","volume":"27","author":"PL Tenore","year":"2008","unstructured":"Tenore PL. Psychotherapeutic benefits of opioid agonist therapy. J Addict Dis. 2008;27(3):49\u201365.","journal-title":"J Addict Dis"},{"issue":"4","key":"1247_CR20","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1080\/17425255.2018.1459564","volume":"14","author":"RM Ragguett","year":"2018","unstructured":"Ragguett RM, et al. Pharmacodynamic and pharmacokinetic evaluation of buprenorphine + samidorphan for the treatment of major depressive disorder. Expert Opin Drug Metab Toxicol. 2018;14(4):475\u201382.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"1247_CR21","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.jad.2024.07.030","volume":"362","author":"S Wong","year":"2024","unstructured":"Wong S, et al. Preclinical and clinical efficacy of kappa opioid receptor antagonists for depression: a systematic review. J Affect Disord. 2024;362:816\u201327.","journal-title":"J Affect Disord"},{"issue":"3","key":"1247_CR22","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.pharmthera.2009.05.008","volume":"123","author":"WA Carlezon Jr","year":"2009","unstructured":"Carlezon WA Jr, et al. Kappa-opioid ligands in the study and treatment of mood disorders. Pharmacol Ther. 2009;123(3):334\u201343.","journal-title":"Pharmacol Ther"},{"issue":"3","key":"1247_CR23","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.tins.2012.11.002","volume":"36","author":"PE Lutz","year":"2013","unstructured":"Lutz PE, Kieffer BL. Opioid receptors: distinct roles in mood disorders. Trends Neurosci. 2013;36(3):195\u2013206.","journal-title":"Trends Neurosci"},{"issue":"4","key":"1247_CR24","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1152\/physrev.00005.2009","volume":"89","author":"J Le Merrer","year":"2009","unstructured":"Le Merrer J, et al. Reward processing by the opioid system in the brain. Physiol Rev. 2009;89(4):1379\u2013412.","journal-title":"Physiol Rev"},{"issue":"3","key":"1247_CR25","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.conb.2004.05.005","volume":"14","author":"C Contet","year":"2004","unstructured":"Contet C, Kieffer BL, Befort K. Mu opioid receptor: a gateway to drug addiction. Curr Opin Neurobiol. 2004;14(3):370\u20138.","journal-title":"Curr Opin Neurobiol"},{"issue":"14","key":"1247_CR26","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.2174\/138161209788168100","volume":"15","author":"E Berrocoso","year":"2009","unstructured":"Berrocoso E, et al. Opiates as antidepressants. Curr Pharm Des. 2009;15(14):1612\u201322.","journal-title":"Curr Pharm Des"},{"issue":"6","key":"1247_CR27","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1001\/archpsyc.1980.01780190040005","volume":"37","author":"RH Gerner","year":"1980","unstructured":"Gerner RH. \u03b2-endorphin. Intravenous infusion causes behavioral change in psychiatric inpatients. Arch Gen Psychiatry. 1980;37(6):642\u20137.","journal-title":"Arch Gen Psychiatry"},{"issue":"11","key":"1247_CR28","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1038\/mp.2013.96","volume":"18","author":"DT Hsu","year":"2013","unstructured":"Hsu DT, et al. Response of the mu-opioid system to social rejection and acceptance. Mol Psychiatry. 2013;18(11):1211\u20137.","journal-title":"Mol Psychiatry"},{"issue":"5","key":"1247_CR29","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/s41386-021-00974-y","volume":"46","author":"PE Lutz","year":"2021","unstructured":"Lutz PE, et al. Increased functional coupling of the mu opioid receptor in the anterior insula of depressed individuals. Neuropsychopharmacology. 2021;46(5):920\u20137.","journal-title":"Neuropsychopharmacology"},{"key":"1247_CR30","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2022.114787","volume":"316","author":"A Escelsior","year":"2022","unstructured":"Escelsior A, et al. Evidence of alterations of beta-endorphin levels and mu-opioid receptor gene expression in bipolar disorder. Psychiatry Res. 2022;316:114787.","journal-title":"Psychiatry Res"},{"key":"1247_CR31","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/164_2020_431","volume":"271","author":"M Spetea","year":"2022","unstructured":"Spetea M, Schmidhammer H. Kappa opioid receptor ligands and pharmacology: diphenethylamines, a class of structurally distinct, selective kappa opioid ligands. Handb Exp Pharmacol. 2022;271:163\u201395.","journal-title":"Handb Exp Pharmacol"},{"issue":"3","key":"1247_CR32","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/00044067-200507000-00003","volume":"16","author":"JE Holden","year":"2005","unstructured":"Holden JE, Jeong Y, Forrest JM. The endogenous opioid system and clinical pain management. AACN Clin Issues. 2005;16(3):291\u2013301.","journal-title":"AACN Clin Issues"},{"issue":"4765","key":"1247_CR33","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1126\/science.3016896","volume":"233","author":"A Pfeiffer","year":"1986","unstructured":"Pfeiffer A, et al. Psychotomimesis mediated by kappa opiate receptors. Science. 1986;233(4765):774\u20136.","journal-title":"Science"},{"key":"1247_CR34","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.brainres.2009.09.074","volume":"1314","author":"AT Knoll","year":"2010","unstructured":"Knoll AT, Carlezon WA Jr. Dynorphin, stress, and depression. Brain Res. 2010;1314:56\u201373.","journal-title":"Brain Res"},{"key":"1247_CR35","doi-asserted-by":"publisher","unstructured":"Gefke M. Clinical use of opioid receptor modulators in bipolar disorder. 2024. https:\/\/doi.org\/10.17605\/OSF.IO\/YFXV5.","DOI":"10.17605\/OSF.IO\/YFXV5"},{"issue":"3","key":"1247_CR36","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/ALN.0000000000004622","volume":"139","author":"M van Lemmen","year":"2023","unstructured":"van Lemmen M, et al. Opioid overdose: limitations in naloxone reversal of respiratory depression and prevention of cardiac arrest. Anesthesiology. 2023;139(3):342\u201353.","journal-title":"Anesthesiology"},{"issue":"4","key":"1247_CR37","first-page":"1030","volume":"52","author":"S Kagawa","year":"1982","unstructured":"Kagawa S, et al. No effect of naloxone on hypoxia-induced ventilatory depression in adults. J Appl Physiol Respir Environ Exerc Physiol. 1982;52(4):1030\u20134.","journal-title":"J Appl Physiol Respir Environ Exerc Physiol"},{"issue":"8084","key":"1247_CR38","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S0140-6736(78)91725-7","volume":"2","author":"D Janowsky","year":"1978","unstructured":"Janowsky D, et al. Naloxone effects on manic symptoms and growth-hormone levels. Lancet. 1978;2(8084):320.","journal-title":"Lancet"},{"issue":"5","key":"1247_CR39","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1001\/archpsyc.1980.01780180097012","volume":"37","author":"LL Judd","year":"1980","unstructured":"Judd LL, et al. Naloxone-induced behavioral and physiological effects in normal and manic subjects. Arch Gen Psychiatry. 1980;37(5):583\u20136.","journal-title":"Arch Gen Psychiatry"},{"issue":"12","key":"1247_CR40","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1176\/ajp.137.12.1583","volume":"137","author":"GC Davis","year":"1980","unstructured":"Davis GC, et al. Failure of naloxone to reduce manic symptoms. Am J Psychiatry. 1980;137(12):1583\u20135.","journal-title":"Am J Psychiatry"},{"issue":"3","key":"1247_CR41","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1001\/archpsyc.1982.04290030047009","volume":"39","author":"D Pickar","year":"1982","unstructured":"Pickar D. Short-term naloxone administration in schizophrenic and manic patients. A World Health Organization collaborative study. Arch Gen Psychiatry. 1982;39(3):313\u20139.","journal-title":"Arch Gen Psychiatry"},{"issue":"3","key":"1247_CR42","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1159\/000117845","volume":"7","author":"WM Verhoeven","year":"1981","unstructured":"Verhoeven WM, van Praag HM, de Jong JT. Use of naloxone in schizophrenic psychoses and manic syndromes. Neuropsychobiology. 1981;7(3):159\u201368.","journal-title":"Neuropsychobiology"},{"key":"1247_CR43","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1192\/bjp.138.6.501","volume":"138","author":"BB Sethi","year":"1981","unstructured":"Sethi BB, Prakash R. A study of naloxone with schizophrenic and manic patients. Br J Psychiatry. 1981;138:501\u20133.","journal-title":"Br J Psychiatry"},{"issue":"6","key":"1247_CR44","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/BF01186014","volume":"14","author":"RR Lideman","year":"1984","unstructured":"Lideman RR, et al. Effect of naloxone on the state of patients with endogenous psychoses. Neurosci Behav Physiol. 1984;14(6):471\u20135.","journal-title":"Neurosci Behav Physiol"},{"issue":"15","key":"1247_CR45","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1093\/ajhp\/zxz105","volume":"76","author":"JL Koehl","year":"2019","unstructured":"Koehl JL, Zimmerman DE, Bridgeman PJ. Medications for management of opioid use disorder. Am J Health Syst Pharm. 2019;76(15):1097\u2013103.","journal-title":"Am J Health Syst Pharm"},{"issue":"3","key":"1247_CR46","doi-asserted-by":"crossref","first-page":"224","DOI":"10.34172\/ahj.1494","volume":"16","author":"R Kumar","year":"2024","unstructured":"Kumar R, et al. Naltrexone and its effects on craving and alcohol use among patients with alcohol dependence syndroms: a report. Addict Health. 2024;16(3):224\u20137.","journal-title":"Addict Health"},{"issue":"12","key":"1247_CR47","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1001\/archpsyc.1997.01830240090013","volume":"54","author":"RS Croop","year":"1997","unstructured":"Croop RS, Faulkner EB, Labriola DF. The safety profile of naltrexone in the treatment of alcoholism. Results from a multicenter usage study. The naltrexone usage study group. Arch Gen Psychiatry. 1997;54(12):1130\u20135.","journal-title":"Arch Gen Psychiatry"},{"issue":"6","key":"1247_CR48","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1177\/0960327112450901","volume":"33","author":"H Hassanian-Moghaddam","year":"2014","unstructured":"Hassanian-Moghaddam H, Afzali S, Pooya A. Withdrawal syndrome caused by naltrexone in opioid abusers. Hum Exp Toxicol. 2014;33(6):561\u20137.","journal-title":"Hum Exp Toxicol"},{"issue":"8","key":"1247_CR49","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/da.20213","volume":"23","author":"ES Brown","year":"2006","unstructured":"Brown ES, et al. Naltrexone in patients with bipolar disorder and alcohol dependence. Depress Anxiety. 2006;23(8):492\u20135.","journal-title":"Depress Anxiety"},{"issue":"11","key":"1247_CR50","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1111\/j.1530-0277.2009.01024.x","volume":"33","author":"ES Brown","year":"2009","unstructured":"Brown ES, et al. A randomized, double-blind, placebo-controlled pilot study of naltrexone in outpatients with bipolar disorder and alcohol dependence. Alcohol Clin Exp Res. 2009;33(11):1863\u20139.","journal-title":"Alcohol Clin Exp Res"},{"issue":"6","key":"1247_CR51","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1097\/JCP.0000000000000222","volume":"34","author":"BL Murphy","year":"2014","unstructured":"Murphy BL, et al. Naltrexone in bipolar disorder with depression: a double-blind, placebo-controlled study. J Clin Psychopharmacol. 2014;34(6):749\u201351.","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"1247_CR52","doi-asserted-by":"crossref","first-page":"102","DOI":"10.4088\/JCP.v67n0114","volume":"67","author":"BI Goldstein","year":"2006","unstructured":"Goldstein BI, Velyvis VP, Parikh SV. The association between moderate alcohol use and illness severity in bipolar disorder: a preliminary report. J Clin Psychiatry. 2006;67(1):102\u20136.","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"1247_CR53","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.bpa.2020.06.005","volume":"34","author":"I Urits","year":"2020","unstructured":"Urits I, et al. The utilization of buprenorphine in chronic pain. Best Pract Res Clin Anaesthesiol. 2020;34(3):355\u201368.","journal-title":"Best Pract Res Clin Anaesthesiol"},{"key":"1247_CR54","doi-asserted-by":"crossref","DOI":"10.52965\/001c.129552","volume":"13","author":"P Brown","year":"2025","unstructured":"Brown P, et al. Methadone for chronic pain: a review of pharmacology, efficacy, and safety concerns. Health Psychol Res. 2025;13:129552.","journal-title":"Health Psychol Res"},{"issue":"2","key":"1247_CR55","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/0165-1781(92)90089-L","volume":"7","author":"LL Judd","year":"1982","unstructured":"Judd LL, et al. The effect of methadone on the behavioral and neuroendocrine responses of manic patients. Psychiatry Res. 1982;7(2):163\u201370.","journal-title":"Psychiatry Res"},{"key":"1247_CR56","first-page":"43","volume":"7","author":"P Matteo","year":"2005","unstructured":"Matteo P, Icro M. Methadone reduces the need for antipsychotic and antimanic agents in heroin addicts hospitalized for manic and\/or acute psychotic episodes. Heroin Add Rel Clin Probl. 2005;7:43\u20138.","journal-title":"Heroin Add Rel Clin Probl"},{"issue":"1","key":"1247_CR57","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1186\/s12955-020-01599-3","volume":"18","author":"M Mohammadi","year":"2020","unstructured":"Mohammadi M, et al. The effect of methadone on depression among addicts: a systematic review and meta-analysis. Health Qual Life Outcomes. 2020;18(1):373.","journal-title":"Health Qual Life Outcomes"},{"issue":"1","key":"1247_CR58","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1151\/spp021113","volume":"1","author":"TR Kosten","year":"2002","unstructured":"Kosten TR, George TP. The neurobiology of opioid dependence: implications for treatment. Sci Pract Perspect. 2002;1(1):13\u201320.","journal-title":"Sci Pract Perspect"},{"issue":"9","key":"1247_CR59","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1111\/pan.15135","volume":"35","author":"T Omori","year":"2025","unstructured":"Omori T, Aoyama T, Tsuji Y. Pentazocine pharmacodynamics in children: simulations to assess safety and effectiveness. Paediatr Anaesth. 2025;35(9):732\u20139.","journal-title":"Paediatr Anaesth"},{"issue":"3\u20134","key":"1247_CR60","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/0376-8716(85)90064-X","volume":"14","author":"G Goldstein","year":"1985","unstructured":"Goldstein G. Pentazocine. Drug Alcohol Depend. 1985;14(3\u20134):313\u201323.","journal-title":"Drug Alcohol Depend"},{"key":"1247_CR61","doi-asserted-by":"crossref","unstructured":"Gandhi KH, James W, Viscusi ER. Chapter 61-Treatment of pain, in pharmacology and therapeutics, principles to practice. In: Waldman ATSA, Woosley RL (eds.) 2009, Elsevier.","DOI":"10.1016\/B978-1-4160-3291-5.50065-2"},{"issue":"2","key":"1247_CR62","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1017\/S1461145707008073","volume":"11","author":"BM Cohen","year":"2008","unstructured":"Cohen BM, Murphy B. The effects of pentazocine, a kappa agonist, in patients with mania. Int J Neuropsychopharmacol. 2008;11(2):243\u20137.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"2","key":"1247_CR63","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s002130100788","volume":"157","author":"SL Walsh","year":"2001","unstructured":"Walsh SL, et al. Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans. Psychopharmacology. 2001;157(2):151\u201362.","journal-title":"Psychopharmacology"},{"issue":"1","key":"1247_CR64","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0022-3565(24)29312-5","volume":"299","author":"SL Walsh","year":"2001","unstructured":"Walsh SL, et al. Enadoline and butorphanol: evaluation of kappa-agonists on cocaine pharmacodynamics and cocaine self-administration in humans. J Pharmacol Exp Ther. 2001;299(1):147\u201358.","journal-title":"J Pharmacol Exp Ther"},{"key":"1247_CR65","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.2147\/JPR.S231948","volume":"12","author":"JV Pergolizzi Jr.","year":"2019","unstructured":"Pergolizzi JV Jr., Raffa RB. Safety and efficacy of the unique opioid buprenorphine for the treatment of chronic pain. J Pain Res. 2019;12:3299\u2013317.","journal-title":"J Pain Res"},{"issue":"5","key":"1247_CR66","doi-asserted-by":"crossref","first-page":"362","DOI":"10.5055\/jom.2019.0525","volume":"15","author":"N Khalili","year":"2019","unstructured":"Khalili N, et al. A double blind randomized clinical trial of buprenorphine augmentation for treatment of psychotic symptoms in opioid addicted bipolar patients. J Opioid Manag. 2019;15(5):362\u20136.","journal-title":"J Opioid Manag"},{"issue":"6","key":"1247_CR67","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1017\/S0033291720000525","volume":"50","author":"CA Madison","year":"2020","unstructured":"Madison CA, Eitan S. Buprenorphine: prospective novel therapy for depression and PTSD. Psychol Med. 2020;50(6):881\u201393.","journal-title":"Psychol Med"},{"key":"1247_CR68","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.jpsychires.2023.03.037","volume":"161","author":"NB Riblet","year":"2023","unstructured":"Riblet NB, et al. The efficacy and safety of buprenorphine for the treatment of depression: a systematic review and meta-analysis. J Psychiatr Res. 2023;161:393\u2013401.","journal-title":"J Psychiatr Res"},{"issue":"5","key":"1247_CR69","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1176\/appi.ajp.2015.15040535","volume":"173","author":"Y Yovell","year":"2016","unstructured":"Yovell Y, et al. Ultra-low-dose buprenorphine as a time-limited treatment for severe suicidal ideation: a randomized controlled trial. Am J Psychiatry. 2016;173(5):491\u20138.","journal-title":"Am J Psychiatry"},{"issue":"6","key":"1247_CR70","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1038\/npp.2014.330","volume":"40","author":"E Ehrich","year":"2015","unstructured":"Ehrich E, et al. Evaluation of opioid modulation in major depressive disorder. Neuropsychopharmacology. 2015;40(6):1448\u201355.","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"1247_CR71","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1176\/appi.ajp.2015.15070921","volume":"173","author":"M Fava","year":"2016","unstructured":"Fava M, et al. Opioid modulation with buprenorphine\/samidorphan as adjunctive treatment for inadequate response to antidepressants: a randomized double-blind placebo-controlled trial. Am J Psychiatry. 2016;173(5):499\u2013508.","journal-title":"Am J Psychiatry"},{"key":"1247_CR72","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3390\/ph18020208","volume":"18","author":"S Schreiber","year":"2025","unstructured":"Schreiber S, Keidan L, Pick C. A new trick of old dogs: can kappa opioid receptor antagonist properties of antidepressants assist in treating treatment-resistant depression (TRD). Pharmaceuticals. 2025;18:208.","journal-title":"Pharmaceuticals"},{"key":"1247_CR73","doi-asserted-by":"crossref","first-page":"174480691775414","DOI":"10.1177\/1744806917754142","volume":"14","author":"I Weinsanto","year":"2018","unstructured":"Weinsanto I, et al. Lithium reverses mechanical allodynia through a mu opioid-dependent mechanism. Mol Pain. 2018;14:1744806917754142.","journal-title":"Mol Pain"},{"issue":"3","key":"1247_CR74","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1080\/09540261.2020.1854194","volume":"33","author":"LA Jelen","year":"2021","unstructured":"Jelen LA, Stone JM. Ketamine for depression. Int Rev Psychiatry. 2021;33(3):207\u201328.","journal-title":"Int Rev Psychiatry"},{"issue":"5","key":"1247_CR75","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1073\/pnas.1916570117","volume":"117","author":"ME Klein","year":"2020","unstructured":"Klein ME, et al. Opioid system is necessary but not sufficient for antidepressive actions of ketamine in rodents. Proc Natl Acad Sci U S A. 2020;117(5):2656\u201362.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"1247_CR76","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1176\/appi.ajp.2018.18020138","volume":"175","author":"NR Williams","year":"2018","unstructured":"Williams NR, et al. Attenuation of antidepressant effects of ketamine by opioid receptor antagonism. Am J Psychiatry. 2018;175(12):1205\u201315.","journal-title":"Am J Psychiatry"},{"key":"1247_CR77","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jad.2016.08.029","volume":"208","author":"D Mischoulon","year":"2017","unstructured":"Mischoulon D, et al. Randomized, proof-of-concept trial of low dose naltrexone for patients with breakthrough symptoms of major depressive disorder on antidepressants. J Affect Disord. 2017;208:6\u201314.","journal-title":"J Affect Disord"},{"issue":"12","key":"1247_CR78","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1007\/s40265-021-01568-0","volume":"81","author":"J Paik","year":"2021","unstructured":"Paik J. Olanzapine\/samidorphan: first approval. Drugs. 2021;81(12):1431\u20136.","journal-title":"Drugs"},{"key":"1247_CR79","volume":"79","author":"ST Rehan","year":"2022","unstructured":"Rehan ST, et al. Samidorphan\/olanzapine combination therapy for schizophrenia: efficacy, tolerance and adverse outcomes of regimen, evidence-based review of clinical trials. Ann Med Surg (Lond). 2022;79:104115.","journal-title":"Ann Med Surg (Lond)"},{"key":"1247_CR80","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.peptides.2019.04.008","volume":"116","author":"RJ Bodnar","year":"2019","unstructured":"Bodnar RJ. Endogenous opioid modulation of food intake and body weight: implications for opioid influences upon motivation and addiction. Peptides. 2019;116:42\u201362.","journal-title":"Peptides"},{"key":"1247_CR81","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jad.2022.01.004","volume":"301","author":"MY Jawad","year":"2022","unstructured":"Jawad MY, et al. Olanzapine and samidorphan combination treatment: a systematic review. J Affect Disord. 2022;301:99\u2013106.","journal-title":"J Affect Disord"},{"issue":"7","key":"1247_CR82","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.biopsych.2019.05.012","volume":"86","author":"SD Clark","year":"2019","unstructured":"Clark SD, Abi-Dargham A. The role of dynorphin and the kappa opioid receptor in the symptomatology of schizophrenia: a review of the evidence. Biol Psychiatry. 2019;86(7):502\u201311.","journal-title":"Biol Psychiatry"},{"key":"1247_CR83","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/164_2020_396","volume":"271","author":"SD Clark","year":"2022","unstructured":"Clark SD. The role of dynorphin and the kappa opioid receptor in schizophrenia and major depressive disorder: a translational approach. Handb Exp Pharmacol. 2022;271:525\u201346.","journal-title":"Handb Exp Pharmacol"},{"issue":"4","key":"1247_CR84","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1097\/FTD.0b013e3181816214","volume":"30","author":"J Dowling","year":"2008","unstructured":"Dowling J, et al. Population pharmacokinetics of intravenous, intramuscular, and intranasal naloxone in human volunteers. Ther Drug Monit. 2008;30(4):490\u20136.","journal-title":"Ther Drug Monit"},{"key":"1247_CR85","unstructured":"Inc, N.T., Study to assess the Effects of oral NMRA-335140 in Participants with Major Depressive Disorder. 2023-2025, National Library of Medicine: Clinical Trials. NCT06058039"},{"key":"1247_CR86","unstructured":"Inc, N.T., Study to assess the effects of oral NMRA-335140 Versus placebo in Participants with Major Depressive Disorder. 2023-2025, National Library of Medicine: Clinical Trials. NCT06058013"},{"key":"1247_CR87","unstructured":"Inc, N.T., Study to Evaluate the effects of oral NMRA-335140 Versus placebo in Participants with Major Depressive Disorder. 2023-2025, National Library of Medicine: Clinical Trials. NCT06029426"},{"key":"1247_CR88","unstructured":"Inc, N.T., Study to Assess the Safety and Effectiveness of NMRA-335140-501. 2023-2026, National Library of Medicine: Clinical Trials. NCT06029439"},{"key":"1247_CR89","unstructured":"Inc, N.T., To Evaluate the Effects of NMRA-335140 on Symptoms of Major Depression in Participants with Bipolar II Disorder. 2024-2025, National Library of Medicine: Clinical trials. NCT06429722"},{"key":"1247_CR90","unstructured":"LLC, J.R.A.D., A study of Aticaprant 10 mg as Adjunctive therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate-to-Severe Anhedonia and Inadequate Response to current Antidepressant Therapy and long-term extension Treatment with Aticaprant (VENTURA-7). 2024-2026, National library of Medicine (U.S.): Clinical trials. NCT06514742"},{"key":"1247_CR91","unstructured":"LLC, J.R.A.D., A study of aticaprant 10 milligrams (mg) as adjunctive therapy in adult participants with MDD with moderate-to-severe anhedonia and inadequate response to current antidepressant therapy (VENTURA-2). 2022-2025, National library of Medicine: Clinical trials. NCT05550532"},{"key":"1247_CR92","unstructured":"LLC, J.R.A.D., A study of aticaprant plus an antidepressant to prevent return of depression symptoms in participants with major depressive disorder who experience a loss of interest and pleasure (VENTURA-5). 2024-2027, National Library of Medicine: Clinical trials. NCT06635135"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01247-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-025-01247-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01247-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T21:02:24Z","timestamp":1767646944000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-025-01247-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,12]]},"references-count":92,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["1247"],"URL":"https:\/\/doi.org\/10.1007\/s40263-025-01247-8","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,12]]},"assertion":[{"value":"20 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"No conflicts of interest exist, neither financial nor personal between the individual authors or the organization and the study subject to bias the outcome of the results. MV has, within the last 3 years, received honoraria from Eli Lilly, Lundbeck Pharma, and Johnson & Johnson. Dr. Roger S. McIntyre has received research grant support from CIHR\/GACD\/National Natural Science Foundation of China (NSFC) and the Milken Institute; and speaker\/consultation fees from Lundbeck, Hanssen, Alkermes, Neumora Therapeutics, Boehringer Ingelheim, Sage, Biogen, Mitsubishi Tanabe, Purdue, Pfizer, Otsuka, Takeda, Neurocrine, Neurawell, Sunovion, Bausch Health, Axsome, Novo Nordisk, Kris, Sanofi, Eisai, Intracellular, NewBridge Pharmaceuticals, Viatris, Abbvie, and Atai Life sciences.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"All data analyzed for this study have been published in this article.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"MV and MG conceived and designed the study and drafted the protocol and the first draft. CW and RM contributed to the conception and design and to revising the following versions. MG and CW undertook data management, searching, screening, and extraction. All authors contributed substantially to the first draft, reviewed and approved the final version of the manuscript, and agree to be accountable for the work.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}